Evaluation of cancer immunotherapy using mini-tumor chips

Area of Science:

• Oncology
• Biotechnology
• Microfluidics

Background:

• Predicting patient response to cancer immunotherapy is crucial for personalized medicine.
• Current methods for evaluating immunotherapy efficacy face significant challenges.
• Integrating tumor pathology and molecular profiles aids treatment decisions.

Purpose of the Study:

• To develop a microfluidics-based mini-tumor chip for predicting tumor responses to cancer immunotherapy.
• To establish a preclinical model for rapid, ex vivo assessment of immunotherapy efficacy.
• To enable personalized prediction of patient response to novel cancer therapies.

Main Methods:

• Uniformly generated 960 mini-tumors on-chip using microfluidic well-arrays.
• Preserved ex vivo tumor niche with original cell composition and cell-cell interactions.
• Utilized time-lapse live-cell imaging to investigate dynamic immune-tumor interactions and treatment responses within 36 hours.

Main Results:

• Demonstrated parallel investigation of immune-tumor interactions and responses to anti-PD1 treatment.
• Successfully predicted in vivo tumor responses to anti-PD1 therapy using early on-chip data from orthotopic breast tumor models.
• Interrogated on-chip responses of primary tumor cells from human breast and renal tissues.

Conclusions:

• The mini-tumor chip offers a simple and rapid solution for measuring tumor responses to cancer immunotherapy.
• This approach facilitates quick-turnaround prediction of treatment efficacy.
• Enables personalized medicine by providing timely data on individual tumor responses to immunotherapy.